Representative before the EPO

Employment test 51 - 200 employees
Company dna mewburn ellis llp
operating since 1890
Headquarter in London and 4 offices
active in Legal Services

We have observed 33 EP applications Emily Anne Luxford Hayes has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12179244

KLOTHO-BETA FOR USE IN TREATING CANCER, LIVER DISORDERS, GALLSTONES, WASTING SYNDROME AND OBESITY-RELATED DISEASES

IPC classification:
A61K 38/17, A61P 1/16, A61P 3/04, A61P 3/06, A61P 3/10, A61P 9/00, A61P 9/12, A61P 11/00, A61P 35/00, G01N 33/74
Applicant:
Genentech, Inc.
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP12725893

METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY

IPC classification:
A61P 35/00, C07K 14/705, C07K 16/28, C07K 16/30, C12N 5/0783
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
GRANT OF PATENT INTENDED
EP12796309

METHODS FOR REPAIRING TISSUE DAMAGE USING PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1

IPC classification:
A61K 38/00
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP11770502

MALARIA VACCINE

IPC classification:
A61K 39/015, C07K 16/20
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Agent:
Robert John Stephen, Olswang LLP
Status:
EXAMINATION IN PROGRESS
EP13189438

Products and methods for stimulating an immune response

IPC classification:
A61K 39/00, A61K 39/385, A61K 39/39
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
PATENT GRANTED
EP13189439

Products and methods for stimulating an immune response

IPC classification:
A61K 39/00, A61K 39/385, A61K 39/39
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12784833

GENETICALLY MODIFIED T CELL RECEPTOR MICE

IPC classification:
A01K 67/027, C07K 14/705
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP12787255

GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE

IPC classification:
A01K 67/027
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
GRANT OF PATENT INTENDED
EP12806199

TRANSGENIC MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II MOLECULES

IPC classification:
A01K 67/027, C07K 14/705
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
GRANT OF PATENT INTENDED
EP11766744

METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

IPC classification:
A61K 39/00, A61K 39/04, C12N 15/86
Applicant:
Massachusetts General Hospital
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14179247

Gene expression and pain

IPC classification:
A61K 48/00, C07H 21/04, C12N 15/113
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
PATENT GRANTED
EP12777107

COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES

IPC classification:
C07K 16/24
Applicant:
Genentech, Inc.
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP13725429

METHODS AND GROUPS

IPC classification:
A61K 38/14, C12Q 1/04
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION REQUESTED
EP14189442

Multivalent antibodies and uses therefor

IPC classification:
A61K 39/395, A61K 47/48, A61K 51/10, C07K 16/00, C07K 16/28, C07K 16/30, C07K 16/32, C07K 19/00, C12N 5/10, C12N 15/13, C12N 15/62
Applicant:
Genentech, Inc.
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
PATENT GRANTED
EP13731479

METHOD FOR REPROGRAMMING SOMATIC CELLS TO PANCREATIC BETA-CELLS

IPC classification:
C12N 5/071, C12N 5/10, C12N 15/85, G01N 33/50
Applicant:
Cancer Research Technology Ltd
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP14748807

METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS

IPC classification:
A61K 35/12, A61K 39/00, C12N 5/10
Applicant:
Massachusetts General Hospital
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
GRANT OF PATENT INTENDED
EP14708429

MICE EXPRESSING HUMANIZED MAJOR HISTOCOMPATIBILITY COMPLEX

IPC classification:
A01K 67/027, C07K 14/705, C07K 14/73, C07K 14/74, C12N 15/85
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION REQUESTED
EP14708430

MICE EXPRESSING HUMANIZED T-CELL CO-RECEPTORS

IPC classification:
A01K 67/027, C07K 14/705, C07K 14/73, C12N 15/85
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP14718815

TRANSGENIC MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II MOLECULES

IPC classification:
A01K 67/027, C07K 14/74
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP14718226

TRANSGENIC MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS I MOLECULES

IPC classification:
A01K 67/027
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION REQUESTED
EP14713567

DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR PROSTATE CANCER AND OTHER DISORDERS

IPC classification:
C12Q 1/68
Applicant:
Cancer Research Technology Ltd
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP14806816

ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE

IPC classification:
A61K 38/00, A61P 35/00
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
GRANT OF PATENT INTENDED
EP12179717

Methods for dectecting autoimmune disorders

IPC classification:
C12Q 1/68
Applicant:
Genentech, Inc.
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP16157878

GENETICALLY MODIFIED MICE AND ENGRAFTMENT

IPC classification:
A01K 67/027, A61K 49/00, C07K 14/52, C07K 14/535, C07K 14/54, C07K 14/715, C12N 9/00
Applicant:
Regeneron Pharmaceuticals Inc
Applicant:
Yale University
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION IN PROGRESS
EP12179733

Methods and compositions for detecting autoimmune disorders

IPC classification:
C12Q 1/68
Applicant:
Genentech, Inc.
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP16161227

NEUTRALIZING HUMAN ANTIBODY MOLECULES FOR IL-13

IPC classification:
A61K 39/00, A61K 39/395, A61P 11/06, A61P 35/00, C07K 16/24, C12N 15/13
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION REQUESTED
EP14869229

METHODS FOR REPAIRING TISSUE DAMAGE USING PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1

IPC classification:
A61K 38/19
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION REQUESTED
EP15832083

OLIGONUCLEOTIDE DECOYS FOR THE TREATMENT OF PAIN

IPC classification:
A61K 31/7088, A61P 25/04, C12N 15/113
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
EXAMINATION REQUESTED
EP15775854

CHIMERIC ANTIGEN RECEPTORS

IPC classification:
A01K 67/027, C07K 14/725, C07K 16/00, C07K 19/00
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
Request for examination was made
EP16199871

GENE EXPRESSION AND PAIN

IPC classification:
A61K 48/00, C07H 21/04, C12N 15/113
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
The application has been published
EP15808501

NON-HUMAN ANIMALS EXPRESSING HUMANIZED CD3 COMPLEX

IPC classification:
A01K 67/027, C07K 14/725, G01N 33/50
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
Request for examination was made
EP15819931

HIGH-THROUGHPUT SEQUENCING OF POLYNUCLEOTIDES

IPC classification:
C12N 15/10, C12Q 1/68
Applicant:
Amyris, Inc.
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
Request for examination was made
EP15816631

NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 274 GENE

IPC classification:
A01K 67/027, A61K 39/00, A61K 39/395, A61P 35/00, C07K 16/22, C07K 16/28, C07K 16/30
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Emily Anne Luxford Hayes, Mewburn Ellis LLP
Status:
Request for examination was made

Please Sign in to use this feature